Correlation of $SUV_{\text{max}}$ and Apparent Diffusion Coefficient Values Detected by Ga-68 PSMA PET/MRI in Primary Prostate Lesions and Their Significance in Lymph Node Metastasis: Preliminary Results of an On-going Study

Ga-68 PSMA PET/MRI ile Tespit Edilen Primer Prostat Lezyonlarında $SUV_{\text{max}}$ ve Görünür Difüzyon Katsayısı Değerlerinin Korelasyonu ve Lefn Nodu Metastazlarında Önemi: Devam Eden Klinik Çalışmanın Ön Buluşları

Abstract

Objectives: Gallium-68 (Ga-68) prostate specific membrane antigen (PSMA) positron emission tomography (PET) has been shown to be more accurate than multiparametric prostate magnetic resonance imaging (MRI) in detection of primary prostate lesions. Using hybrid PET/MRI we aim to detect the correlation between $SUV_{\text{max}}$ and apparent diffusion coefficient (ADC) in primary prostate lesions and to assess their prognostic value in detection of lymph node (LN) metastasis.

Methods: Twenty-six patients, who were diagnosed as having prostate cancer with biopsy and underwent Ga-68 PSMA PET/MRI together with biparametric prostate MRI (bpMRI) were included. $SUV_{\text{max}}$, $SUV_{\text{mean}}$, and ADC were recorded for index lesions drawing a region of interest (ROI) of 1 cm$^2$ around the pixel with the highest $SUV_{\text{max}}$ (ROI-1) and another ROI following borders of prostate tumor detected by bpMRI (ROI-2). Presence of LN metastasis was recorded according to PSMA PET/MRI.

Results: $SUV_{\text{max}}$ was inversely correlated with ADC (ROI-1: $p=0.010$; ROI-2: $p=0.017$ for $b=800$). $SUV_{\text{max}}$ and $SUV_{\text{mean}}$ were both higher in patients with LN metastasis and ADC was lower in patients with LN metastasis for ROI-1. $SUV_{\text{max}}$ cut-off value of 19.8 for ROI-1 and 20.9 for ROI-2 had sensitivity and specificity of 77.8% and 76.5%, respectively for detection of LN metastasis, whereas ADC ($b=800$) cut-off value of $0.92 \times 10^{-3}$ mm$^2$/s had sensitivity and specificity of 87.5% and 76.5%, respectively. $SUV_{\text{max}}$/ADC (b=800) ratio increased the sensitivity and specificity to 100% and 82.4%, respectively.

Conclusion: SUV and ADC values are inversely correlated in primary prostate lesions and the combined use of both values increases the diagnostic accuracy of hybrid PET/MRI in the detection of primary prostate lesions.

Keywords: Gallium-68, prostate specific membrane antigen, positron emission tomography/magnetic resonance imaging, multiparametric prostate magnetic resonance imaging, prostate cancer, lymph node metastasis

Address for Correspondence: Lebriz Uslu-Beşli MD, Istanbul University-Cerrahpasa Faculty of Medicine, Department of Nuclear Medicine, Istanbul, Turkey
Phone: +90 212 414 30 00/22189 E-mail: lebriz.uslu@istanbul.edu.tr ORCID ID: orcid.org/0000-0003-1868-3957
Received: 23.04.2019 Accepted: 30.05.2019

©Copyright 2019 by Turkish Society of Nuclear Medicine
Molecular Imaging and Radionuclide Therapy published by Galenos Yaynevi.
Introduction

Prostate cancer is the second most common diagnosed cancer in men and the fifth leading cause of cancer-related death worldwide (1). Death rates are lower in developed countries, due to early detection of the disease and improved treatment methods (1). Prostate specific antigen (PSA) is a glycoprotein produced by prostate cells and though not specific for prostate cancer, elevated PSA values detected by PSA screening was shown to aid in early diagnosis of prostate cancer, thus decrease prostate cancer-related death rates (2,3,4).

The screening for prostate cancer is generally made by serum PSA level measurement together with digital rectal examination (DRE). Prostate 12-core needle biopsy under transrectal ultrasonography guidance (TRUS-biopsy) is the most common method used for diagnosis of prostate cancer (5). Multiparametric prostate magnetic resonance imaging (mpMRI) has been introduced as a novel imaging approach for diagnosis and localization of primary prostate lesions (6). MpMRI guided prostate biopsy was shown to be more accurate than conventional TRUS-biopsy (7). Therefore, although mpMRI is not routinely recommended as a screening tool for detection of prostate cancer, it is recommended for patients with elevated PSA values despite negative TRUS-biopsy (8,9,10).

The most common sites for metastasis in prostate cancer are bones (84%), distant lymph nodes (LN) (10.6%), liver (10.2%) and thorax (9.1%) (11). However, magnetic resonance imaging (MRI) alone has limited value in detection of LN and distant organ metastasis.

Prostate specific membrane antigen (PSMA), which functions on cell membrane as glutamate carboxypeptidase-2 or folate hydrolase, was shown to be over-expressed in prostate cancer cells (12), which led to the introduction of Ga-68 labeled urea-based PSMA inhibitor (Ga-68-PSMA-HBED-CC) as a novel positron emission tomography (PET) tracer used for staging of patients with prostate cancer with high accuracy, for detection of LN and organ metastasis, as well as for detection of residual or recurrent local disease (13). PSMA overexpression in prostate cancer cells was shown to be associated with higher prostate cancer grade, resulting in higher incidence of metastasis and castration resistance (14). Similarly, apparent diffusion coefficient (ADC) value obtained from diffusion-weighted imaging (DWI) component of mpMRI was shown to be inversely correlated with Gleason score and was reported to provide quantitative information on tumor characteristics and aggressiveness (15). Hybrid PET/MRI systems have also been shown to be more accurate than mpMRI in terms of detecting primary prostate lesions (16,17).

The aim of our study is to detect the correlation between maximum and mean standardized uptake value ($SV_{max}$ and $SV_{mean}$) and ADC values of primary prostate lesions and to assess the prognostic value of $SV_{max}$ and ADC in terms of detecting LN metastasis.

Materials and Methods

This retrospective study was approved by Istanbul University Clinical Research Ethics Committee (14/01/2019-6927) and conducted between May 2017 and April 2018. All procedures performed in this study involving human participants were in accordance with the ethical standards of the Institutional and/or National Research Committee...
and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

**Study Population**

Twenty-six patients, with a mean age of 67.5±7.0 years (median age: 67.5, range: 50-83 years), who were diagnosed as having prostate cancer using TRUS-biopsy and underwent whole body Ga-68 PSMA PET/computerized tomography (PET/CT) or PET/MRI together with prostate PET/MRI including biparametric-MRI (bpMRI) sequences were included in our retrospective analysis. The patients had elevated serum PSA values (mean: 65.2±199.6 ng/mL, median: 21.4 ng/mL, range: 5.4-934 ng/mL) and they did not receive any previous treatment or did not undergo any operation related with prostate cancer or with benign prostate hyperplasia previously. Patient characteristics are given in Table 1.

**Imaging**

For Ga-68 PSMA PET imaging, all patients were injected Ga-68-PSMA-HBED-CC with a mean activity of 255.3±77.7 MBq (6.9±2.1 mCi), intravenously. Radiolabeling procedure was performed using a fully automated radiopharmaceutical synthesis device based on a modular concept (Eckert & Ziegler Eurotope, Berlin, Germany) as described previously by Kabasakal et al. (18).

All PET/MRI images were acquired using an integrated 3 Tesla - PET/MRI scanner (GE Signa PET/MRI, GE Healthcare, Waukesha, Wisconsin, USA). Prostate PET/MRI including bpMRI was acquired at mean 104.9±43.6 minutes post-injection including an initial localizer scan, a 3D dual-echo fast spoiled gradient recalled echo liver-accelerated volume acquisition sequence (LAVA-FLEX) for MRI based attenuation correction (MRAC), followed by a high-resolution axial T1-weighted (T1W) 3D LAVA-FLEX sequence, T2-weighted (T2W) periodically rotated overlapping parallel lines technique at 3-planes (axial, sagittal and coronal) and field of view optimized and constrained undistorted single shot (FOCUS) DWI (b values: 50-400-800 and 50-1400) and ADC mapping. PET emission scan was recorded together with MRI sequences and acquisition time per bed position was 3.5 min. PET attenuation correction was performed using vendor-based algorithm including MRAC data and atlas-based attenuation correction map.

A total of 10 patients had a whole-body PET/MRI at mean 87.5±20.3 minutes post-injection in the caudo-cranial direction from mid-thigh to vertex, including an initial localizer scan, 3D LAVA-FLEX for MRAC, high-resolution axial T1W 3D LAVA-FLEX sequence, coronal T2W short-tau inversion recovery (STIR), axial DWI (b values: 50-1000) and ADC mapping.

A total of 16 patients had whole-body Ga-68 PSMA PET/CT images acquired prior prostate PET/MRI using an integrated PET/CT scanner (Siemens Biograph 6, Knoxville, TN, USA or GE Discovery 710, Waukesha, WI, USA) at 71.6±14.4 minutes post-injection. An initial CT topogram was followed by a CT transmission scan and an emission PET scan in the caudo-cranial direction from mid-thigh to vertex. Imaging parameters for transmission CT scan were as follows: Low tube current (130 kVp 48-76 mAs), slice thickness of 4.0 mm, gantry rotation time of 0.6 s and collimator width of 6x3 mm. PET emission scan was acquired at 2-4 min per bed position (GE Discovery PET/CT: 2 min/bed, Siemens Biography 6 PET/CT: 4 min/bed) at caudo-cranial direction. Iterative image reconstruction method using CT transmission images were utilized for attenuation correction. All patients were asked to empty bladder before initiation of whole-body PET/CT or PET/MRI as well as prostate PET/MRI acquisition to minimize bladder activity.

**Image Analysis**

All whole-body PET images (PET/CT and PET/MRI) were reviewed and analyzed by two nuclear medicine physicians (LUB and SA) together and all prostate PET/MRI images including bpMRI sequences were reviewed together with a radiologist (BB) and a nuclear medicine physician (LUB) together using vendor-based work station (GE AW Volume

| Table 1. Patient characteristics |
|----------------------------------|
| Age (mean±SD) | 67.9±7.0 years |
| Gleason scores (n) | 12 |
| 3+4 | 5 |
| 4+3 | 4 |
| 4+4 | 2 |
| 5+4 | 1 |
| 5+5 | 1 |
| Mean serum PSA value (mean±SD) | 65.2±199.6 ng/mL |
| Presence of lymph node metastasis (n) | 9 |
| Presence of bone metastasis (n) | 3 |
| Presence of visceral organ metastasis (n) | 0 |
| Whole body PET/CT (n) | 16 |
| Whole body PET/MRI (n) | 10 |
| Mean Ga-68 PSMA activity (mean±SD) | 255.3±77.7 MBq (6.9±2.1 mCi) |

SD: Standard deviation, PSA: Prostate specific antigen, PET/CT: Positron emission tomography/computed tomography, MRI: Magnetic resonance imaging, PSMA: Prostate specific membrane antigen, Ga-68: Gallium-68
Localization and extension of the primary tumor in the prostate gland was recorded on a prostate scheme for both PET and MRI data separately. **SUV**\(_{\text{max}}\) and mean ADC (ADC) were measured drawing region of interest (ROI) 1 cm\(^2\) around the pixel with the highest **SUV**\(_{\text{max}}\) in the prostate tumor (ROI-1) and another ROI following the borders of prostate tumor (ROI-2) detected by bpMRI. Whole-body PET images were used to detect presence of LN and organ metastasis.

**Statistical Analysis**

Statistical analysis was performed using SPSS software version 21.0 (IBM Corp., Armonk, New York, USA) and the level of significance was taken as p value less than 0.05. Pearson correlation analysis was performed to observe the relationship between SUV and ADC values. Mann-Whitney U test was performed to analyze the relationship between LN metastasis status and SUV and ADC values. Receiver operating characteristic (ROC) curve analysis was calculated to assess the ability to discriminate the LN metastasis status based on SUV and ADC values.

**Results**

**SUV**\(_{\text{max}}\), **SUV**\(_{\text{mean}}\) and ADC values (for both b=1400 and b=800) obtained from ROI-1 and ROI-2 of the prostate lesion were given in Table 2.

For both ROI-1 and ROI-2, **SUV**\(_{\text{max}}\) value was inversely correlated with both ADC (b=1400) value (ROI-1: p=0.026, r=-0.444; ROI-2: p=0.032, r=-0.429) and ADC (b=800) value (ROI-1: p=0.010, r=-0.506; ROI-2: p=0.017, r=-0.473) (Table 3). Also, **SUV**\(_{\text{mean}}\) value was inversely correlated with both ADC (b=1400) value (ROI-1: p=0.013, r=-0.488; ROI-2: p=0.018, r=-0.468) and ADC (b=800) value (ROI-1: p=0.004, r=-0.553; ROI-2: p=0.009, r=-0.508) for both ROI-1 and ROI-2 (Figure 1A, 1B).

**SUV**\(_{\text{max}}\) and **SUV**\(_{\text{mean}}\) were significantly higher in patients with LN metastasis for both ROI-1 and ROI-2 (ROI-1: p=0.01 and p=0.01; ROI-2: p=0.02 and p=0.01, respectively) (Table 4) (Figures 2, 3). Although ADC values were significantly lower in patients with LN metastasis for ROI-1 (p=0.04 for b=1400 and p=0.02 for b=800), there was no significant difference in terms of ADC values in patients with LN metastasis for ROI-2. The ratios of **SUV**\(_{\text{max}}\)/ADC and

---

**Table 2. Mean maximum and mean standardized uptake values and apparent diffusion coefficient values of prostate lesions obtained from drawing 2 different region of interests**

| ROI-1 | Mean±SD | Range |
|-------|---------|-------|
| **SUV**\(_{\text{max}}\) | 23.3±25.5 | 2.9-122.5 |
| **SUV**\(_{\text{mean}}\) | 16.7±16.1 | 2.3-71.7 |
| ADC (b=1400) (x 10\(^{-3}\) mm\(^2\)/s) | 0.87±0.19 | 0.41-1.39 |
| ADC (b=800) (x 10\(^{-3}\) mm\(^2\)/s) | 0.97±0.21 | 0.56-1.39 |

| ROI-2 | Mean±SD | Range |
|-------|---------|-------|
| **SUV**\(_{\text{max}}\) | 21.2±22.9 | 2.7-117.9 |
| **SUV**\(_{\text{mean}}\) | 14.5±14.1 | 2.0-70.4 |
| ADC (b=1400) (x 10\(^{-3}\) mm\(^2\)/s) | 0.78±0.16 | 0.42-1.19 |
| ADC (b=800) (x 10\(^{-3}\) mm\(^2\)/s) | 0.98±0.22 | 0.55-1.53 |

ROI: Region of interest, ADC: Apparent diffusion coefficient, SD: Standard deviation.

---

**Figure 1.** Both **SUV**\(_{\text{max}}\) and **SUV**\(_{\text{mean}}\) values were found to be inversely correlated with ADC values (both for b=1400 and b=800) for ROI-1 (A) and ROI-2 (B). **SUV**\(_{\text{max}}\): Maximum standardized uptake value, **SUV**\(_{\text{mean}}\): Mean standardized uptake value, **ADC**\(_{\text{mean}}\): Mean apparent diffusion coefficient value, ROI: Region of interest.
SUV\textsubscript{mean}/ADC for both b values (b=1400 and b=800) were significantly higher in patients with LN metastasis for both ROI-1 and ROI-2 (Table 4).

ROC analysis revealed that SUV\textsubscript{max} cut-off level of 19.8 for ROI-1 and 20.9 for ROI-2 predicted the presence of LN metastasis with sensitivity of 77.8% and specificity of 76.5% (Table 5). For SUV\textsubscript{mean}, cut-off level of 16.3 for ROI-1 and 10.8 for ROI-2 had sensitivity of 77.8% and 88.9% and specificity of 82.4% and 76.5%, respectively. For ADC (b=800) and ADC (b=1400) cut-off levels of 0.92x10\(^{-3}\) mm\(^2\)/s and 0.82x10\(^{-3}\) mm\(^2\)/s had sensitivities of 87.5% and 50% and specificities of 76.5% and 82.4%, respectively in prediction of LN metastasis. When SUV/ADC ratios were taken for both SUV\textsubscript{max} and SUV\textsubscript{mean} values as well as for both ADC values; sensitivity and specificity increased to 100% and 82.4%, respectively for ROI-1 and to 87.5% and 82.4%, respectively for ROI-2 (Table 5).

**Discussion**

MIPMRI has been introduced as a novel imaging approach for diagnosis, localization and characterization of primary prostate lesions and has been shown to have a good sensitivity for detecting clinically significant prostate cancer and guiding prostate biopsy (19,20). However, despite its several advantages, MIPMRI has also some limitations, including poor detection of low-grade disease, low inter-observer agreement, poor quality images within six weeks after TRUS-biopsy due to residual hemorrhage and inflammation, limited patient cooperation, especially in

### Table 3. Correlation analysis between maximum and mean standardized uptake value and apparent diffusion coefficient

| ROI-1          | p       | r       |
|----------------|---------|---------|
| SUV\textsubscript{max} - ADC (b=1400) | 0.026   | -0.444  |
| SUV\textsubscript{max} - ADC (b=800)  | 0.010   | -0.506  |
| SUV\textsubscript{mean} - ADC (b=1400) | 0.013   | -0.488  |
| SUV\textsubscript{mean} - ADC (b=800)  | 0.004   | -0.553  |

| ROI-2          | p       | r       |
|----------------|---------|---------|
| SUV\textsubscript{max} - ADC (b=1400) | 0.032   | -0.429  |
| SUV\textsubscript{max} - ADC (b=800)  | 0.017   | -0.473  |
| SUV\textsubscript{mean} - ADC (b=1400) | 0.018   | -0.468  |
| SUV\textsubscript{mean} - ADC (b=800)  | 0.009   | -0.508  |

ROI: Region of interest, ADC: Apparent diffusion coefficient
claustrophobic patients and lower sensitivity in transitional zone tumors (19,21). Ga-68 PSMA PET/CT and PET/MRI, on the other hand were shown to have better sensitivity and higher diagnostic accuracy than mpMRI in the detection of primary prostate cancer, both in index lesions and in cases of multifocal disease (17,22,23,24).

Ga-68 PSMA uptake was shown to be correlated with tumor Gleason score, serum PSA levels, PI-RADS category and DRE findings (25). ADC value obtained by mpMRI was also found to be correlated with Gleason scores (26,27), serum PSA levels (28), molecular markers (29) and was introduced to be a promising tool to monitor therapy.

### Table 4. Comparison of standardized uptake value parameters and apparent diffusion coefficient values according to presence of lymph node metastasis

| ROI-1       | Lymph node metastasis (+) | Lymph node metastasis (-) | p    |
|-------------|----------------------------|---------------------------|------|
|             | Mean±SD | Median (range) | Mean±SD | Median (range) |      |
| SUV<sub>max</sub> | 42.1±34.7 | 33.9 (5.9-122.5) | 13.4±10.4 | 7.9 (2.9-37.7) | 0.01 |
| SUV<sub>mean</sub>  | 29.6±20.4 | 26.7 (4.7-71.7) | 9.9±7.5 | 6.2 (2.3-29.6) | 0.01 |
| ADC<sub>b=1400</sub> (x10⁻³ mm²/s) | 0.82±0.14 | 0.84 (0.63-1.03) | 0.89±0.21 | 0.87 (0.41-1.39) | 0.04 |
| ADC<sub>b=800</sub> (x10⁻³ mm²/s) | 0.84±0.06 | 0.84 (0.75-0.92) | 1.04±0.23 | 1.10 (0.56-1.39) | 0.02 |
| SUV<sub>mean</sub>/ADC<sub>b=1400</sub> | 57.5±59.6 | 40.9 (6.3-194.4) | 19.0±22.4 | 9.1 (2.1-92.0) | 0.01 |
| SUV<sub>mean</sub>/ADC<sub>b=800</sub> | 57.0±46.1 | 42.4 (22.9-163.3) | 15.4±16.5 | 7.7 (2.1-67.3) | 0.01 |
| SUV<sub>max</sub>/ADC<sub>b=1400</sub> | 39.6±34.5 | 30.1 (5.0-113.8) | 14.2±17.3 | 7.2 (1.7-72.2) | 0.01 |
| SUV<sub>max</sub>/ADC<sub>b=800</sub> | 39.6±25.8 | 32.8 (16.2-95.6) | 11.4±12.6 | 6.0 (1.7-52.9) | 0.01 |

ROI-2

| ROI-2       | Lymph node metastasis (+) | Lymph node metastasis (-) | p    |
|-------------|----------------------------|---------------------------|------|
|             | Mean±SD | Median (range) | Mean±SD | Median (range) |      |
| SUV<sub>max</sub> | 35.6±32.2 | 26.9 (5.9-117.9) | 13.5±11.0 | 7.8 (2.7-35.7) | 0.02 |
| SUV<sub>mean</sub>  | 24.5±18.9 | 19.8 (4.6-70.4) | 9.1±6.7 | 5.6 (2.0-22.7) | 0.01 |
| ADC<sub>b=1400</sub> (x10⁻³ mm²/s) | 0.74±0.15 | 0.75 (0.52-0.95) | 0.80±0.18 | 0.82 (0.42-1.19) | 0.49 |
| ADC<sub>b=800</sub> (x10⁻³ mm²/s) | 0.89±0.15 | 0.90 (0.69-1.13) | 1.01±0.24 | 1.06 (0.55-1.53) | 0.15 |
| SUV<sub>max</sub>/ADC<sub>b=1400</sub> | 53.0±55.1 | 37.9 (6.2-183.6) | 20.3±21.4 | 9.2 (2.5-82.2) | 0.01 |
| SUV<sub>max</sub>/ADC<sub>b=800</sub> | 47.2±44.6 | 33.1 (15.8-155.8) | 16.0±16.6 | 7.6 (2.0-62.5) | 0.01 |
| SUV<sub>mean</sub>/ADC<sub>b=1400</sub> | 35.8±32.5 | 27.2 (4.9-109.6) | 13.8±13.9 | 7.2 (1.7-53.7) | 0.02 |
| SUV<sub>mean</sub>/ADC<sub>b=800</sub> | 32.1±25.7 | 23.8 (9.9-93.0) | 10.8±10.8 | 5.9 (1.3-40.9) | 0.01 |

ROI: Region of interest, SD: Standard deviation, ADC: Apparent diffusion coefficient

### Table 5. Sensitivity of specificity of different standardized uptake value parameters and apparent diffusion coefficient values in terms of prediction of lymph node metastasis

| ROI-1       | Cut-off level | Sensitivity | Specificity |
|-------------|--------------|-------------|-------------|
| SUV<sub>max</sub> | 19.8         | 77.8%       | 76.5%       |
| SUV<sub>mean</sub>  | 16.3         | 77.8%       | 82.4%       |
| ADC<sub>b=1400</sub> (x10⁻³ mm²/s) | 0.82         | 50%         | 82.4%       |
| ADC<sub>b=800</sub> (x10⁻³ mm²/s) | 0.92         | 87.5%       | 76.5%       |
| SUV<sub>mean</sub>/ADC<sub>b=800</sub> | 22.5         | 100%        | 82.4%       |
| SUV<sub>max</sub>/ADC<sub>b=800</sub> | 15.5         | 100%        | 82.4%       |

ROI-2

| ROI-2       | Cut-off level | Sensitivity | Specificity |
|-------------|--------------|-------------|-------------|
| SUV<sub>max</sub> | 20.9         | 77.8%       | 76.5%       |
| SUV<sub>mean</sub>  | 10.8         | 88.9%       | 76.5%       |
| SUV<sub>mean</sub>/ADC<sub>b=800</sub> | 27.6         | 87.5%       | 82.4%       |
| SUV<sub>max</sub>/ADC<sub>b=800</sub> | 17.2         | 87.5%       | 82.4%       |

ROI: Region of interest, ADC: Apparent diffusion coefficient
response (30,31). To our knowledge, PSMA uptake and ADC values were not compared before using hybrid PET/MRI or PET/CT systems. However, an inverse correlation between PSMA uptake and ADC values in primary prostate tumor is an expected finding according to the current literature.

Hybrid PET/MRI systems provide better anatomical delineation of prostate gland compared to hybrid PET/CT systems due to better soft-tissue resolution of the MRI component, and enable one-stop-shop imaging for prostate cancer patients, including Ga-68 PSMA PET and mpMRI in a single session. Therefore, PET/MRI has more potential to aside misdiagnosis due to physiological or false-positive PSMA uptake in the prostate gland (32,33). Also, simultaneous acquisition of PET and MRI images could provide additional advantages, which are not provided by PET/CT systems. However, to date, there are still limited number of studies on Ga-68 PSMA PET/MRI in evaluation of primary prostate tumor and in its diagnostic accuracy compared to PET/CT or mpMRI.

We found higher SUV$_{\text{max}}$ and SUV$_{\text{mean}}$ values and lower ADC values in patients with LN metastasis, which may be due to the presence of more aggressive tumor with higher Gleason scores, that were documented to have both higher PSMA uptake and lower ADC values in the literature (26,27,34). Concomitant usage of SUV and ADC parameters by using the ratio of SUV/ADC further increased the sensitivity and specificity of PET/MRI imaging in predicting LN metastasis.

**Study Limitations**

The main limitation in our study was the lack of post-operative histopathological result in our cohort and the small sample size. Therefore, we could not compare PSMA uptake with Gleason scores and we had to evaluate the status of LN metastasis only by Ga-68 PSMA PET imaging.

**Conclusion**

SUV and ADC values are inversely correlated in primary prostate lesions and the combined use of both values increases the diagnostic accuracy of hybrid PET/MRI in the detection of primary prostate lesions. SUV$_{\text{max}}$, SUV$_{\text{mean}}$, and ADC detected by Ga-68 PSMA PET/MRI are future promising new prognostic values for detecting LN metastasis in prostate cancer patients.

**Ethics**

**Ethics Committee Approval:** This retrospective study was approved by Istanbul University Clinical Research Ethics Committee (14/01/2019-6927).

**Informed Consent:** Retrospective study.

**Peer-review:** Externally peer-reviewed.

**Authorship Contributions**

Surgical and Medical Practices: L.U.B., B.B., E.G., Ç.D., E.K.; Concept: L.U.B., B.B., H.B.S., K.S.; Design: L.U.B., B.B.; Data Collection or Processing: L.U.B., S.A., E.G., O.E.Ş.; Analysis or Interpretation: L.U.B., B.B., S.S., H.B.S., K.S.; Literature Search: L.U.B., M.S.S.; Writing: L.U.B., B.B., S.A., O.E.Ş., S.S.

**Conflict of Interest:** No conflict of interest was declared by the authors.

**Financial Disclosure:** The authors declared that this study received no financial support.

**References**

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwanckowski M, Lujan M, Lilja H, Zappa M, Denis Ll, Recker F, Paez A, Mäittäinen L, Bangma CH, Aus G, Carlsson S, Villers A, Rebillard X, van der Kwast T, Kujala PM, Blijenberg BG, Stenman UH, Huber A, Taari K, Hakama M, Moss SM, de Koning HJ, Auvinen A; ERSPC Investigators. Prostate-Cancer Mortality at 11 Years of Follow-up. N Engl J Med 2012;366:981-990.
3. Schröder FH, Hugosson J, Roobol MJ, Tammela TL, Zappa M, Nelen V, Kwanckowski M, Lujan M, Mäittäinen L, Lilja H, Denis Ll, Recker F Paez A, Bangma CH, Carlsson S, Puli D, Villers A, Rebillard X, Hakama M, Stenman UH, Kujala P, Taari K, Aus G, Huber A, van der Kwast TH, van Schalk RH, de Koning HJ, Moss SM, Auvinen A; ERSPC Investigators. Screening and prostate cancer mortality: Results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet 2014;384:2027-2035.
4. Tsodikov A, Gilat R, Etzioni R. Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials. Ann Intern Med 2018;168:608-609.
5. Cuzick J, Thorat MA, Andriole G, Brawley OW, Brown PH, Culig Z, Eeles RA, Ford LG, Hamdy FC, Holmberg L, Ilc D, Key TJ, La Vecchia C, Lilja H, Marberger M, Meyskens FL, Miniasian LM, Parker C, Parnes HL, Perner S, Rittenhouse H, Schalken J, Schmid HP, Schmitz-Dräger BJ, Schröder FH, Sterof A, Tombal B, Wilt TJ, Wolk A. Prevention and early detection of prostate cancer. Lancet Oncol 2014;15:484-492.
6. Marberger M, Barentsz J, Emberton M, Hugosson J, Loeb S, Klotz L, Koch M, Shariat SE Vickers A. Novel approaches to improve prostate cancer diagnosis and management in early-stage disease. BJU Int 2012;109(Suppl 2):1-7.
7. Sonn GA, Natarajan S, Margolis DJ, MacAiran M, Lieu P, Hwang J, Dorey FJ, Marks LS. Targeted biopsy in the Detection of Prostate Cancer Using an Office Based Magnetic Resonance Ultrasound Fusion Device. J Urol 2013;189:186-189.
8. Carroll PR, Parsons JK, Andriole G, Bahnsen RR, Barcos DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein J, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Polch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Spenrek F, Vickers AJ, Wake R, Shead DA, Friedman-Cass D. NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015. J Natl Compr Canc Netw 2015;13:1534-1561.
9. Heidenreich A, Bastian PJ, Bellmunt J, Bolla M, Joniau S, van der Kwast T, Mason M, Matveev V, Siegel RL, Dorey FJ, Marks LS. Targeted biopsy in the Detection of Prostate Cancer Using an Office Based Magnetic Resonance Ultrasound Fusion Device. J Urol 2013;189:186-189.
10. Carroll PR, Parsons JK, Andriole G, Bahnsen RR, Barcos DA, Castle EP, Catalona WJ, Dahl DM, Davis JW, Epstein J, Etzioni RB, Farrington T, Hemstreet GP 3rd, Kawachi MH, Lange PH, Loughlin KR, Lowrance W, Maroni P, Mohler J, Morgan TM, Nadler RB, Polch M, Scales C, Shaneyfelt TM, Smaldone MC, Sonn G, Spenrek F, Vickers AJ, Wake R, Shead DA, Friedman-Cass D. NCCN Clinical Practice Guidelines Prostate Cancer Early Detection, Version 2.2015. J Natl Compr Canc Netw 2015;13:1534-1561.
Association of Urology. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014;65:124-137.

10. Rosenkranz AB, Verma S, Choyke P, Eberhardt SC, Eggener SE, Gaitonde K, Haider MA, Margolis DJ, Marks LS, Pinto P, Sonn GA, Taneja SS. Prostate Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Patients with a Prior Negative Biopsy: A Consensus Statement by ALUA and SAR. J Urol 2016;196:1613-1618.

11. Gandaglia G, Abdullah J, Schifffmann J, Trudeau V, Shariat SE, Kim SE, Perrotte F, Montorsi F, Briganti A, Trinh QD, Karakiewicz PI, Sun M. Distribution of metastatic sites in patients with prostate cancer: a population-based analysis. Prostate 2014;74:210-216.

12. Barinka C, Rojas C, Slusher B, Pomper M. Glutamate Carboxypeptidase II in Diagnosis and Treatment of Neurological Disorders and Prostate Cancer. Curr Med Chem 2012;19:856-870.

13. Li Q, Xiang F, Lin X, Grajo JR, Yang L, Xu Y, Duan Y, Vyas U, Harisinghani M, Mahmood U, Samir AE. The Role of Imaging in Prostate Cancer Care Pathway: Novel Approaches to Urologic Management Challenges Along 10 Imaging Touch Points. Urology 2018;119:23-31.

14. Bravaccini S, Puccetti M, Bochioni M, Ravaiolli S, Celli M, Scarpi E, De Giorgi U, Tumedef MM, Rulli G, Cardinale L, Paganelli G. PSMA expression: A potential ally for the pathologist in prostate cancer diagnosis. Sci Rep 2018;8:4254.

15. Park SY, Kim CK, Park BK, Lee HM, Lee KS. Prediction of biochemical recurrence following radical prostatectomy in men with prostate cancer by diffusion-weighted magnetic resonance imaging: Initial results. Eur Radiol 2011;21:1111-1118.

16. Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, Beer AL, Wester HJ, Gschwend J, Schwaiger M, Maurer T. Simultaneous 68Ga-PSMA HBED-CC PET/MRI Improves the Localization of Primary Prostate Cancer. Eur Urol 2016;70:829-836.

17. Hicks RM, Simko JP, Westphalen AC, Nguyen HG, Greene KL, Zhang L, Carroll PR, Hope TA. Diagnostic Accuracy of 68 Ga-PSMA-11 PET / MRI Compared with Multiparametric MRI in the Detection of Prostate Cancer. Radiology 2016;281:730-737.

18. Kabsasak L, Demirci E, Ocak M, Akyl R, Nemattazar J, Aygun A, Halac M, Talat Z, Araman A. Evaluation of PSMA PET/CT imaging using a 68Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun 2015;36:582-587.

19. Greer MD, Choyke PL, Turkbey B. PI-RADSv2: How we do it. J Magn Reson Imaging Touch Points. Urology 2018;119:23-31.

20. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Greer MD, Choyke PL, Turkbey B. PI-RADSv2: How we do it. J Magn Reson Imaging Touch Points. Urology 2018;119:23-31.

21. Wang X, Bao J, Ping X, Hu C, Hou J, Dong F, Guo L. The diagnostic value of PI-RADS V1 and V2 using multiparametric MRI in transition zone prostate clinical cancer. Oncol Lett 2018;16:3201-3206.

22. Berger I, Annabattula C, Lewis J, Shetty DV, Kam J, Maclean F, Arianayagam M, Canagasingham B, Ferguson R, Khadra M, Ko R, Winter M, Loh H, Varol C. 68Ga-PSMA PET/CT vs. mpMRI for locoregional prostate cancer staging: correlation with final histopathology. Prostate Cancer Prost Dis 2018;21:204-211.

23. Donato P, Roberts MJ, Morton A, Kyle S, Coughlin G, Eser R, Dunglison N, Gardiner RA, Yaaxley J. Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions "invisible" on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology. Eur J Nucl Med Mol Imaging 2019;46:20-30.

24. Al-Bayati M, Grueneisen J, Lüttje S, Sawicki LM, Unharalingam S, Tschirnwehn S, Forsting M, Röbben H, Herrmann K, Umutlu L, Wetter A. Integrated 68 Gallium Labelled Prostate-Specific Membrane Antigen-11 Positron Emission Tomography/Magnetic Resonance Imaging Enhances Discriminatory Power of Multi-Parametric Prostate Magnetic Resonance Imaging. Urol Int 2018;100:164-171.

25. Jena A, Taneja R, Taneja S, Singh A, Kumar V, Agarwal A, Subramanian N. Improving diagnosis of primary prostate cancer with combined 68Ga-prostate-specific membrane antigen-HBED-CC simultaneous PET and multiparametric MRI and clinical parameters. J Am J Roentgenol 2018;211:1246-1253.

26. Jyoti R, Jain TP, Haxhimolla H, Liddell H, Barrett SE. Correlation of apparent diffusion coefficient ratio on 3.0 T MRI with prostate cancer Gleason score. Eur J Radiol Open 2018;5:58-63.

27. Sokmen BK, Sokmen D, Ucar N, Ozkurt H, Simsek A. The correlation between biological activity and diffusion-weighted MR imaging and ADC value in cases with prostate cancer. Arch Ital Urol Androl 2017;89:277-281.

28. Iraha Y, Murayama S, Kamiya I, Iraha S, Ogawa K. Diffusion-weighted MRI and PSA correlations in patients with prostate cancer treated with radiation and hormonal therapy. Anticancer Res 2012;32:4467-4471.

29. Ma T, Yang S, Jing H, Cong L, Cao Z, Liu Z, Huang Z. Apparent diffusion coefficients in prostate cancer: correlation with molecular markers Ki-67, HIF-1α and VEGF NMR Biomed 2018:31.

30. Kim AY, Kim CK, Park SY, Park BK. Diffusion-Weighted Imaging to Evaluate for Changes From Androgen Deprivation Therapy in Prostate Cancer. Am J Roentgenol 2014;203:645-650.

31. Qi WX, Zhang Q, Li P, Zhang XM, Zhang GY, Wu B, Lu JJ, Jiang GL, Fu S. The predictive role of ADC values in prostate cancer patients treated with carbon-ion radiotherapy: initial clinical experience at Shanghai Proton and Heavy Ion Center (SPHIC). J Cancer Res Clin Oncol 2016;142:1361-1367.

32. Ferraro DA, Rupp NJ, Donati OF, Messeri M, Eberli D, Burger IA. 68Ga-PSMA-11 PET/MR Can Be False Positive in Normal Prostatic Tissue. J Nucl Med 2019;60:257-258.

33. Pizzuto DA, Müller J, Mühlematter U, Rupp NJ, Töpfer A, Mortezavi A, Nadel H, Kranzbühler B, Eberli D, Burger IA. The central zone has increased 68Ga-PSMA-11 uptake: “Mickey Mouse ears” can be hot on 68Ga-PSMA PET/MRI. Nucl Med Commun 2019;44:291-293.

34. Jena A, Taneja R, Taneja S, Singh A, Kumar V, Agarwal A, Subramanian N. Improving Diagnosis of Primary Prostate Cancer With Combined 68Ga-Prostate-Specific Membrane Antigen-HBED-CC Simultaneous PET and Multiparametric MRI and Clinical Parameters. AJR Am J Roentgenol 2018;211:1246-1253.